Trends were observed for higher VEGFR2 H-score expression in more undifferentiated carcinomas (Gleason ≥7) (P = 0.099) and in patients with PSA ≥ 10 ng/mL (P = 0.085), and for positive CAIX expression in prostate carcinomas from patients with PSA above 10 ng/mL (P = 0.078). This evidence concerns the gene KLK3 and prostate carcinoma.